Drug Profile
Autologous gamma delta T cell therapy - TC BioPharm
Alternative Names: Autologous γδ T Lymphocytes; Gamma-delta T cell therapy; Immunicell; TCB-001; TCB-101; γδ T lymphocytes - TC BioPharmLatest Information Update: 17 Mar 2022
Price :
$50
*
At a glance
- Originator TC BioPharm
- Developer Medinet; TC BioPharm
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer